Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men
优化对高度脆弱的使用甲基苯丙胺的性少数男性的艾滋病毒预防
基本信息
- 批准号:10462053
- 负责人:
- 金额:$ 195万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-08 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAddressBehaviorBiologicalCaringClinicalComplexContinuity of Patient CareEffectivenessEnrollmentEpidemicFundingGoalsHIVHIV InfectionsHIV SeropositivityHIV riskHealthHuman immunodeficiency virus testHybridsImmuneIncentivesIncidenceInterventionLawsMethamphetamineMethodologyMotivationParticipantPeer ReviewPharmaceutical PreparationsPoliciesPrevalenceRandomized Controlled TrialsReadinessReportingRiskRoleSamplingScienceSocial NetworkTelephoneTestingToxicologyagedbiobehaviorchemokineclinically relevantcohortcomorbiditycomparativecontingency managementcytokinedensitydesigndigitaleffectiveness testingethnic minorityevidence basehigh riskimplementation sciencemen of colormethamphetamine usemethamphetamine usermotivational enhancement therapypeople of colorpre-exposure prophylaxisprimary outcomeprospectivepsychologicpsychosocialpublic health interventionracial and ethnicracial disparityrecruitrectalresponsesexual minoritysexual minority groupsexual minority mensocialsocial determinantssocial stigmasoundsuccesssyndemictelehealthtransmission processvirtual
项目摘要
SUMMARY
This LITE-2 (RFA-AI-21-018) initiative responds to a resurgent epidemic of methamphetamine (meth) use in
sexual minority men (SMM), which is a primary driver of HIV incidence. The overarching goals are two-fold:
1) identify multi-level and bio-behavioral determinants of amplified HIV seroconversion risk in meth-using SMM;
and 2) test the effectiveness of telehealth motivational enhancement interventions for optimizing entry or re-entry
of SMM who use meth into the PrEP care continuum. Findings from our LITE-1 cohort (UG3/UH3 AI-133675,
RFA-AI-16-031) and others provide compelling evidence that meth use is increasing, disproportionally impacts
racial/ethnic minorities, and accounts for one-in-three new HIV infections in SMM. In response to LITE-2 (RFA-
AI-21-018) we propose a multi-component initiative zeroing in on the “Where,” “How,” and “Why” of meth use
and HIV risk. Where: What are the geospatial determinants of the association of meth use with HIV incidence?
How: How can we support (re-)entry into the PrEP care continuum with this high priority population of SMM who
use meth? Why: Does meth amplify biological risk of HIV by potentiating rectal immune dysregulation? Aim 1:
Examine multi-level structural, psychological, and social determinants of amplified HIV seroconversion risk in
SMM who use meth. The centerpiece of our LITE-2 initiative is a new prospective, bio-behavioral cohort with
N=5,000 SMM (n=3,000 SMM who use meth, n=2,000 who do not). Participants will complete assessments over
36 months and provide biological samples for HIV testing, drug toxicology testing, rectal STIs, and rectal
cytokines/chemokines. Our primary goal will be to investigate the role of geospatial determinants (e.g.,
background meth and HIV prevalence, urbanicity) and other structural determinants (e.g., structural stigma of
sexual minorities as evidenced by policies/laws) in relation to the association of meth use with amplified HIV
seroconversion risk. Aim 2: Test the comparative and combined effectiveness of telehealth motivational
enhancement interventions for optimizing PrEP use. PrEP Readiness Interventions for Supporting Motivation
(PRISM) is a hybrid type I, modified factorial randomized controlled trial (RCT) of telehealth CM that provides
incentives for filling a PrEP prescription, and a 2-session telehealth MI intervention that we adapted with meth-
using SMM (R34-DA046367, Carrico/Grov). PRISM will enroll 840 meth-using SMM who are not currently taking
PrEP from the LITE-2 cohort (Aim 1) to examine the effectiveness of CM (n = 280), MI (n = 280), and MI+CM (n
= 280) on the primary outcome – filling a PrEP prescription. Aim 3: Determine whether greater rectal immune
dysregulation partially explains amplified risk of HIV seroconversion in SMM who use meth. Using a case-cohort
design, we will compare HIV seroconverters (n=450) with matched seronegative controls (n=450) to examine
the clinical relevance of meth-induced alterations in rectal cytokines with respect to HIV seroconversion. This
LITE-2 initiative could have an exceptional impact by transforming HIV prevention with SMM.
总结
这一LITE-2(RFA-AI-21-018)举措是为了应对在阿富汗重新流行的甲基苯丙胺(冰毒)使用,
性少数男性(SMM),这是艾滋病毒发病率的主要驱动因素。总体目标有两个方面:
1)确定吸毒SMM中HIV血清转化风险扩大的多水平和生物行为决定因素;
测试远程保健动机增强干预措施对优化进入或再进入的有效性
在PrEP护理中使用冰毒的SMM患者。来自我们的LITE-1队列的发现(UG 3/UH 3 AI-133675,
RFA-AI-16-031)和其他人提供了令人信服的证据,表明冰毒的使用正在增加,
少数种族/族裔,占SMM新感染艾滋病毒的三分之一。根据LITE-2(RFA-
AI-21-018)我们提出了一个多组件的倡议,集中在“在哪里”,“如何”和“为什么”使用冰毒
艾滋病风险。地点:冰毒使用与艾滋病毒发病率相关的地理空间决定因素是什么?
如何:我们如何支持(重新)进入PrEP护理连续体,这是SMM的高优先级人群,
用冰毒吗原因:冰毒是否通过增强直肠免疫失调来放大HIV的生物风险?目标1:
研究艾滋病毒血清转换风险扩大的多层次结构、心理和社会决定因素,
吸食冰毒的人。我们LITE-2计划的核心是一个新的前瞻性生物行为队列,
N= 5,000 SMM(n= 3,000 SMM使用冰毒,n= 2,000不使用)。参与者将完成评估,
36个月,并提供生物样本,用于艾滋病毒检测,药物毒理学检测,直肠性传播感染,
细胞因子/趋化因子。我们的主要目标是调查地理空间决定因素的作用(例如,
背景方法和艾滋病毒流行率,城市化)和其他结构性决定因素(例如,结构性柱头
政策/法律所证明的性少数群体)与使用冰毒与艾滋病毒扩增之间的联系
血清转化风险。目的2:测试远程医疗激励的比较和组合效果
优化PrEP使用的强化干预措施。PrEP准备干预支持动机
(PRISM)是一项混合I型、改良析因随机对照试验(RCT),提供远程医疗CM,
激励填写PrEP处方,和2个会话远程医疗MI干预,我们适应了甲基-
使用SMM(R34-DA 046367,Carrico/Grov)。PRISM将招募840名目前未服用
来自LITE-2队列(目标1)的PrEP,以检查CM(n = 280)、MI(n = 280)和MI+CM(n = 280)的有效性
= 280)的主要结果-填写PrEP处方。目的3:确定直肠免疫是否
失调部分解释了使用冰毒的SMM中艾滋病毒血清转化的风险放大。使用病例队列
设计,我们将比较HIV血清转换者(n=450)与匹配的血清阴性对照(n=450),以检查
甲硫氨酸诱导的直肠细胞因子改变与HIV血清转换的临床相关性。这
LITE-2倡议可以通过用SMM改变艾滋病毒预防产生特殊的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Wayne Carrico其他文献
Adam Wayne Carrico的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Wayne Carrico', 18)}}的其他基金
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.
建立美国国家队列以改善使用兴奋剂的艾滋病毒男性感染者的病毒抑制。
- 批准号:
10675863 - 财政年份:2023
- 资助金额:
$ 195万 - 项目类别:
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection
甲基苯丙胺使用、病毒库动态与治疗艾滋病毒感染的临床进展之间的关系
- 批准号:
10683495 - 财政年份:2023
- 资助金额:
$ 195万 - 项目类别:
Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men
支持治疗依从性以促进复原力和繁荣 (START):一项移动医疗干预措施,旨在提高使用兴奋剂的 HIV 阳性男性的 ART 依从性
- 批准号:
10895784 - 财政年份:2023
- 资助金额:
$ 195万 - 项目类别:
Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men
支持治疗依从性以促进复原力和繁荣 (START):一项移动医疗干预措施,旨在提高使用兴奋剂的 HIV 阳性男性的 ART 依从性
- 批准号:
10898254 - 财政年份:2023
- 资助金额:
$ 195万 - 项目类别:
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
用于治疗 HIV 诊所兴奋剂使用的 reSET:护理优化支持治疗依从性 (COSTA)
- 批准号:
10553554 - 财政年份:2022
- 资助金额:
$ 195万 - 项目类别:
Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men
优化对高度脆弱的使用甲基苯丙胺的性少数男性的艾滋病毒预防
- 批准号:
10606596 - 财政年份:2022
- 资助金额:
$ 195万 - 项目类别:
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
调查抑郁症对神经免疫目标影响的治疗研究 (TRIDENT)
- 批准号:
10700126 - 财政年份:2021
- 资助金额:
$ 195万 - 项目类别:
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
调查抑郁症对神经免疫目标影响的治疗研究 (TRIDENT)
- 批准号:
10369905 - 财政年份:2021
- 资助金额:
$ 195万 - 项目类别:
Optimizing PrEP adherence in sexual minority men who use stimulants
优化使用兴奋剂的性少数男性的 PrEP 依从性
- 批准号:
10404091 - 财政年份:2020
- 资助金额:
$ 195万 - 项目类别:
Optimizing PrEP adherence in sexual minority men who use stimulants
优化使用兴奋剂的性少数男性的 PrEP 依从性
- 批准号:
10894531 - 财政年份:2020
- 资助金额:
$ 195万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 195万 - 项目类别:
Research Grant